Enhancement molecule for Cell Therapy, Gene Editing

Vycellix is focused on advancing next-generation cellular immunotherapies that aim to optimize and enhance cell and gene-based therapies. The company has developed several innovative platforms, including Universal Cells, which are designed to provide allogeneic cell-based therapies with a reduced risk of immune rejection. This technology is pivotal in creating therapies that can be more widely applicable to patients without the complications associated with traditional autologous cell therapies, where cells are sourced from the individual patient.

In addition to Universal Cells, Vycellix emphasizes the importance of cell potency, transduction, and expansion in their therapeutic approaches. These technologies are integral to ensuring that the cells used in therapies are not only effective but also capable of proliferating and functioning optimally within the patient's immune system. The company’s commitment to multi-antigen engagement further enhances the potential of their therapies to target a broader range of diseases, making their offerings significant in the field of immunotherapy.

United States

Vycellix is a biopharmaceutical company developing novel platforms to optimize and enhance cell & gene based-therapies. The company's platforms include VY-UC to generate immune-privileged universal cells without altering the components that control self-recognition (HLA).

Vycellix

Company Details